Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock.

Gallup found 11% of U.S. adults are currently taking GLP-1s for weight loss (vs. 3% in 2024), and 15% have used them at some point—an ongoing demand tailwind for Eli Lilly and Novo Nordisk. Eli Lilly reported Q1 Mounjaro sales of $8.7B and Zepbound sales of $4.2B (combined $12.9B) and raised 2026 revenue guidance to $82.2B–$85B (up $2B). The early-April launch of Lilly’s oral GLP-1 weight-loss drug (Foundayo) may further accelerate sales as consumers shift toward an oral option.

Analysis

The market mechanism here is not just higher unit demand; it is lower uncertainty around the size of the obesity franchise, which supports a higher terminal growth assumption for the category leader. Lilly still looks like the cleaner compounder because it controls the stronger efficacy narrative and now has a second route of administration that can expand adherence and reduce drop-off, which matters more than raw prescription counts over a 6-18 month horizon. Novo remains a share loser unless it can re-accelerate on comparable efficacy or better access terms; otherwise, every incremental patient awareness dollar disproportionately accrues to the incumbent with the deeper pull-through.

Second-order effects are less about the drugmakers and more about the ecosystem: telehealth weight-loss platforms, compounders, and lower-tier obesity programs face compression if branded oral therapy improves convenience and payer acceptance. The immediate 1-3 month catalyst is script data and any payor commentary on coverage, not the launch press cycle; if utilization rises without a matching reimbursement broadening, the category may still be capped to higher-income, cash-pay users. Over 6-12 months, the biggest upside surprise would be oral adoption broadening persistence, which could force upward revisions to peak sales assumptions and keep multiples elevated despite already rich valuations.

The contrarian miss is that awareness does not equal monetization: if the new format mostly cannibalizes injectables rather than expanding treated lives, the headline TAM story is overstated. Lilly’s multiple already prices in durable superiority, so the stock is more exposed to any disappointment in adherence, safety, or payer friction than the recent tone suggests. For Novo, the setup is more asymmetric than the street admits: the bar is low, and any credible share stabilization could squeeze shorts faster than the market expects.

Key Decisions for Investors

• Long LLY / short NVO for 1-3 months: express relative share gains and superior product cadence; target 10-15% spread capture, stop if NVO regains U.S. script momentum or if Lilly launch data disappoints.
• Do not chase LLY outright after the multiple re-rate; if initiating fresh exposure, use a 3-6 month call spread to cap valuation compression risk while preserving upside from continued estimate revisions.
• Watch weekly prescription and payer coverage data as the real catalyst set; if coverage broadens faster than expected, add to LLY on a 5-8% pullback, but if scripts flatten, reduce exposure immediately.
• Consider a short basket of GLP-1-adjacent telehealth/compounding beneficiaries on any strength, as branded oral convenience should pressure lower-quality distribution models over the next 3-6 months.
• If NVO sells off another 10%+ without a deterioration in its own launch metrics, revisit as a contrarian long; the risk/reward improves only when sentiment fully discounts a prolonged share-loss scenario.